Search Results

Where are we now in biologic drugs for myositis?

• Authors : Neves, Ana; Viveiros, Luísa; Venturelli, Veronica

Subjects: BIOTHERAPY; INTRAVENOUS immunoglobulins; MYOSITIS

• Source: Rheumatology; Nov2024, Vol. 63 Issue 11, p2938-2947, 10p

Record details

Biologic disease-modifying anti-rheumatic drugs and kinase inhibitors: differences in efficacy and safety in rheumatoid arthritis.

• Authors : Fleischmann, Roy^1,2 (AUTHOR)

Subjects: *ABATACEPT; *ADALIMUMAB; *KINASE inhibitors

• Source: Clinical Rheumatology. Nov2021, Vol. 40 Issue 11, p4369-4372. 4p.

Record details

Cost-effectiveness of abatacept, tocilizumab and TNF-inhibitors compared with rituximab as second-line biologic drug in rheumatoid arthritis

• Authors : Huoponen, Saara; Aaltonen, Kalle J.; Viikinkoski, Jaana

• Source: PLoS ONE. July 24, 2019, Vol. 14 Issue 7, e0220142

Record details

A Case of Disseminated Histoplasmosis in a Patient with Rheumatoid Arthritis on Abatacept.

• Authors : Jain, Nina; Doyon, Jeffrey B.; Lazarus, Jacob E.

Subjects: BIOLOGICALS; INFECTION; MYCOSES

• Source: JGIM: Journal of General Internal Medicine; May2018, Vol. 33 Issue 5, p769-772, 4p, 1 Color Photograph

Record details

Critical appraisal of efficacy and safety of abatacept in the treatment of refractory rheumatoid arthritis

• Authors : Lundquist, Lisa M.; Cole, Sabrina W.; Augustine, Jill M.

• Source: Open Access Rheumatology: Research and Reviews. January 1, 2012, Vol. 4, p9, 11 p.

Record details

Integrating Nanotechnological Advancements of Disease-Modifying Anti-Rheumatic Drugs into Rheumatoid Arthritis Management.

• Authors : Singh, Sukhbir; Tiwary, Neha; Sharma, Neelam

Subjects: ANTIRHEUMATIC agents; CERTOLIZUMAB pegol; RHEUMATOID arthritis

• Source: Pharmaceuticals (14248247); Feb2024, Vol. 17 Issue 2, p248, 19p

Record details

Recent Research from University of Medicine Berlin Highlight Findings in Rheumatoid Arthritis (Subcutaneous Abatacept for the Treatment of Rheumatoid Arthritis In Routine Clinical Practice In Germany, Austria, and Switzerland: 2-year Retention...).

Subjects: ABATACEPT; DRUGS

• Source: Drug Week; 8/25/2023, p1598-1598, 1p

Record details

Drug adherence to biologic DMARDS with a special emphasis on the benefits of subcutaneous abatacept

• Authors : Malaviya, Anshuman P.; Ostor, Andrew J.K.

• Source: Patient Preference and Adherence. January 1, 2012, Vol. 6, p589, 7 p.

Record details

The Shrinking Value of Best-In-Class & First-In-Class Drugs.

• Authors : LONGMAN, ROGER¹

Subjects: *BUSINESS partnerships; DRUGS; ABATACEPTBRISTOL-Myers Squibb Co. 001288497 BRISTOL-Myers Squibb Co. BRISTOL-Myers Squibb Co. 001288497 001288497 BRISTOL-Myers Squibb Co. 001288497 BMY; REGENERON Pharmaceuticals Inc. 194873139 REGENERON Pharmaceuticals Inc. REGENERON Pharmaceuticals Inc. 194873139 194873139 REGENERON Pharmaceuticals Inc. 194873139 REGN; SANOFI SA

• Source: IN VIVO. Jul/Aug2015, Vol. 33 Issue 7, p8-12. 5p.

Record details

A Study to Evaluate the Drug Levels of Abatacept Converted From Drug Substance by Two Different Processes in Healthy Participants.

Subjects: ABATACEPT; VITAL signs; DIRECTLY observed therapy

• Source: TB & Outbreaks Week; 8/24/2023, p302-302, 1p

Record details